Abstract: For optimal efficacy, an inhaler should deliver doses consistently and be easy for patients to use with minimal instruction. The delivery characteristics, patients' correct use, and preference of two single-dose dry powder inhalers (Breezhaler and HandiHaler) were evaluated in two complementary studies. The first study examined aerodynamic particle size distribution, using inhalation profiles of seven patients with moderate to very severe chronic obstructive pulmonary disease (COPD). The second was an open-label, two-period, 7-day crossover study, evaluating use of the inhalers with placebo capsules by 82 patients with mild to severe COPD. Patients' correct use of the inhalers was assessed after reading written instructions on Day 1, and after training and 7 days of daily use. Patients' preference was assessed after completion of both study periods. Patient inhalation profiles showed average peak inspiratory flows of 72 L/minute through Breezhaler and 36 L/minute through HandiHaler. For Breezhaler and HandiHaler, fine particle fractions were 27% and 10%, respectively. In the second study, correct use of Breezhaler and HandiHaler was achieved by .77% of patients for any step after 7 days; 61% of patients showed an overall preference for Breezhaler and 31% for HandiHaler (P = 0.01). Breezhaler is a low-resistance inhaler suitable for use by patients with a range of disease severities. Most patients used both inhalers correctly after 7 days, but more patients showed an overall preference for the Breezhaler compared with the HandiHaler. These are important factors for optimum dose delivery and successful COPD management.
Introduction
A patient's ability to use an inhaler correctly and their preference for the inhaler are both important factors in selecting an appropriate treatment for chronic obstructive pulmonary disease (COPD). 1 Incorrect handling of inhalation devices is common in COPD and is influenced not only by patient-related factors (eg, physical ability) but also by the type of inhaler prescribed and the adequacy of patient education. [2] [3] [4] Poor handling and inhalation technique may result in suboptimal drug delivery to the lower airway, 2, [5] [6] [7] which can ultimately reduce compliance and prevent successful disease management. 8, 9 The aerodynamic size of drug particles generated by inhalers is critical in determining the distribution and deposition of drug within the lung, with the fine particle fraction or FPF (defined as fraction of particles less than 5 µm in diameter) generally considered optimum to deposit in the bronchi and alveoli. Thus, dose delivery from a dry powder inhaler (DPI) depends not only on correct handling and inhalation, but also on the inhaler's internal resistance and its ability to generate sufficient fine High-resistance devices require greater effort by the patient to achieve inspiratory flows adequate to ensure FPF dose delivery, 11 and some patients with significant pulmonary disease cannot generate these flows. 12, 13 Inhaled long-acting bronchodilators are used for the treatment of patients with moderate and more severe COPD, 14 with two agents available for once-daily administration. Indacaterol is a novel, inhaled, once-daily, ultra-long-acting β 2 -agonist 15 delivered by a single-dose DPI known as the Breezhaler ® in some countries, and approved in more than 40 countries for maintenance treatment in COPD. The other once-daily inhaled bronchodilator is the anticholinergic, tiotropium, delivered by a single-dose DPI called the HandiHaler 
Methods
In-vitro dose delivery study
The aerodynamic particle distribution of indacaterol 150 µg via Breezhaler and tiotropium 18 µg via HandiHaler was measured using a standard Next Generation Impactor (NGI, MSP Corporation, Shore view, MN) with pre-separator and induction port coupled to a flow-volume simulator ( Figure 1 ). Neutral sum air flow at experimental rest was required to facilitate particle generation during the simulated breathing maneuvers and was achieved by an auxiliary air supply at the mixing inlet and vacuum pump at the impactor outlet at 100 L/minute and 60 L/minute, respectively, for the Breezhaler and HandiHaler. The patients' breathing patterns were reproduced at the mouthpiece of the DPIs by modulating the air flow using the computer-controlled flow-volume simulator. Three replicate measurements were obtained for each simulated patient flow profile, using a new DPI for each determination. The simulated flow profiles closely resembled the original patient flow profiles with ,3% mean relative difference over all flow values. Seven patient inhalation flow profiles were chosen from a group of profiles obtained from 28 patients. The profiles were selected to cover disease severities from moderate to severe and a representative range of patient age, gender and airflow obstruction. In addition, the technical specification of the experimental apparatus determined that the selected profiles were within maximum peak inspiratory flows of 
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Comparing single-dose dry-powder inhalers in COPD 100 L/minute. This is the maximum possible that can be achieved through the NGI in order to measure aerodynamic particle size distribution when simulating recorded patient flow patterns.
Quantification of indacaterol and tiotropium depositions from the NGI analysis was performed using high-performance liquid chromatography on two samples from each NGI component. Fine particle dose and particle size (defined by median mass aerodynamic diameter) were measured and geometric standard deviation (GSD) determined. GSD is a measure of the variability of the particle diameters within the aerosol. An aerosol with a GSD of 1 is described as monodisperse (uniform diameter distribution); an aerosol with a GSD . 1.2 is heterodisperse (heterogeneous particle distribution). 16 Based on the results of the particle size analysis, the theoretical respiratory tract deposition (extrathoracic, representing the portion 'lost' through oropharyngeal deposition, versus intrathoracic, delivered to the lower airways) for each of the patient breathing profiles was estimated using a semiempirical deposition model for healthy lungs. 17 The in vitro dose delivery study was carried out at Inamed Research GmbH and Co KG, Gauting, Germany.
Assessment of patients' correct use of, and preference for, inhalers 
study design
This was an open-label, multicenter, two-period, 7-day crossover study (Figure 2 ). Patients used Breezhaler or HandiHaler with placebo capsules once daily each for 7 days in random sequence, in addition to their usual treatment. On Day 1, patients were asked to read written instructions for correct use of the inhaler, similar to that provided by the manufacturers with the prescribed medications, and had 30 minutes to practice using the inhaler (without the capsule); they were given no verbal training or demonstration at this time. Patients were then given the blister containing the capsules and asked to demonstrate their use of the inhaler, under the observation of two trained respiratory assessors. This provided an assessment of first use on the basis of written instructions for use only.
The same assessors recorded each patient's ability to perform each of the 21 steps required for correct use of Breezhaler and the 19 steps for HandiHaler, using an assessment checklist for correct use prepared specifically for this study (for details of the checklists, see Table 4 , Results). 
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Steps were classed as correct ('yes' or 'fully completed') or incorrect ('no' or 'not fully completed'). For each inhaler, two steps were identified as critical for appropriate dose delivery: full release of the piercing buttons (allowing capsule rotation), and exhalation away from the mouthpiece before inhalation. Study center personnel then trained the patients verbally and demonstrated (without capsules) how to use the inhaler properly before the patients went home. Training was standardized across the study centers. These procedures were repeated at the start of the second study treatment period. At the end of each treatment period (ie, on Day 7 of each period), patients' correct inhaler use and inhalation technique were re-assessed by the same assessors. After the assessment at the end of the second treatmentperiod, patients were given both inhalers used during the study and had a few minutes to re-familiarize themselves with the two inhalers. They were then asked to complete the patient preference questionnaire (for questionnaire details, see Table 5 , Results). The handling assessment checklist and preference questionnaire were developed by the study sponsor. In the absence of available validated assessment tools, the handling assessment checklist and preference questionnaire were developed using the patient information leaflets for the inhalers and previously published studies investigating inhaler use, and were not validated.
Objectives and outcomes
The primary objective of this study was to assess patients' correct use of the two inhalers after 7 days of daily use, ie, under preferable conditions where the patient has read the instructions for use and has received verbal training and demonstration of correct use. Secondary objectives included the assessment of correct use after reading written instructions on Day 1, the performance of the two critical steps on Days 1 and 7, and patients' preference between the inhalers. The comparison of the total handling scores, calculated from the device handling assessment checklists, and each item of the preference questionnaire, were exploratory objectives.
statistical methods
Results for each step of the device handling assessment checklist were summarized by inhaler type as number and percentage of patients. A step was classified as correct if the response was either 'yes' or 'fully completed'. If the responses differed between the assessors, the step was classed as incorrect. For each patient, a total handling score was calculated as the number (percentage) of checklist items with correct use out of the total number of items. The total handling scores for the two inhalers were summarized as percentages and compared using a mixed analysis of variance model (Stat Proc Mixed) with fixed effects for period and inhaler and a random effect for patient. The difference in total handling score is presented with 95% confidence intervals (CIs) and associated P-value. Responses to each question in the preference questionnaire were summarized by inhaler type as number and percentage of patients. For questions eliciting a preference between the two inhalers a Mainland-Gart test was performed to allow for period effects, ignoring patients showing no preference. For responses on a 10-point scale, a mixed-model analysis of variance was used as described for the total handling score analysis.
A formal sample size calculation was not performed, because the study was exploratory in nature. The total number of 80 patients was chosen based on previous studies that had included approximately 60-70 patients.
19,20

Results
In-vitro dose delivery study
A group of 28 inhalation profiles was reviewed and seven patient inhalation profiles were selected to be representative of a COPD population, including moderate and severe stages of COPD, an approximately equal number of males and females, and a range of ages and inhalation variables (Table 1 and Figure 3 ). The mean FPF was 26.8% of the 150 µg label claim for Breezhaler, while the mean FPF from the HandiHaler was 9.8% of the label claim (18 µg) ( Table 2 ). The two inhalers generated particles of similar uniformity of size, but the mean size of the drug particles from the Breezhaler was smaller than those generated by the HandiHaler (3.2 µm compared with 3.9 µm).
Mean estimated intrathoracic drug deposition as a percentage of the mean delivered dose (Table 2) was 31% for the Breezhaler and 22% for the HandiHaler (Figure 4 ). Mean estimated extrathoracic drug deposition was 57% for Breezhaler and 71% for HandiHaler.
Assessment of patients' correct use of, and preference for, inhalers
Eighty-three patients with COPD severities ranging from mild to severe were randomized. One patient was randomized in error and left the study before any Day 1 procedures had been carried out. This patient was not included in the analysis population, which comprised 82 patients (Table 3) .
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Patients' correct inhaler use
The results for each checklist item on Days 1 and 7 are shown in Table 4 . For most steps, the proportion of patients correctly performing the step increased from Day 1 to Day 7. On Day 7, each step was performed correctly by most patients (78%-100% for Breezhaler; 81%-100% for HandiHaler). For the critical step of fully releasing the button before inhalation, the Breezhaler score was similarly high on both days (93%, 96%), while for the HandiHaler the proportion of patients correctly completing this step changed by 11% from 88% (Day 1) to 99% (Day 7). The other critical step (breathing out away from the inhaler before inhalation) was completed correctly on Day 7 by 85% of patients with Breezhaler and 81% of patients using the HandiHaler. The percentage of patients without a critical error was 81% and 83% on Days 1 and 7, respectively, for Breezhaler, and 70% and 81% on Days 1 and 7, respectively, for HandiHaler.
Total handling scores on Day 7 (least squares means) were 93.5% for Breezhaler and 94.4% for HandiHaler, a mean difference of −1.0 (95% CI −3.0 to 1.1; P = 0.357). On Day 1, scores were 91.8% for Breezhaler and 90.6% for HandiHaler, a difference of 1.2 (95% CI −1.2 to 3.6; P = 0.333).
Patients' inhaler preference
The results of the preference questionnaire are presented in Figures 5 and 6 
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Comparing single-dose dry-powder inhalers in COPD cap and mouthpiece (both P , 0.001), closing the mouthpiece after inserting the capsule (P = 0.005) and holding the inhaler (P , 0.001). There were no statistically significant preferences for HandiHaler. The mean scores for the items scored on a 1-10 scale (comfort of inhalation, simplicity of use and confidence in successful intake of medication) were slightly greater with Breezhaler than with HandiHaler, and the differences in mean score were statistically significant ( Figure 6 ).
Discussion
Breath actuation was a major advantage when DPIs were developed, overcoming problems that patients had in coordinating actuation and inhalation with pressurized metered-dose inhalers. However, breath actuation also meant that patients had to generate an inspiratory effort to overcome the internal resistance of the DPIs. Breezhaler has a lower internal resistance than HandiHaler (specific airflow resistances of 2.2 and 5.1 × 10 −2 kPa ½ L −1 minute, respectively). 21 Thus, the Breezhaler requires less inspiratory effort to achieve a given inspiratory flow or, as reflected in the inspiratory flow profiles, permits a higher inspiratory flow for a given effort. We measured the inhalation patterns of 28 patients, subsequently using the profiles of seven patients as a result of various exclusion criteria, the main one being the 100 L/minute calibration limit of the measuring equipment. This limited the study to the potentially 'poorer' end of the inspiratory profiles for Breezhaler (as the low resistance permits inspiratory flows higher than the set limit) but not for the HandiHaler, since achievable inhalation flow rates for this higher-resistance inhaler would tend to be well within the calibration limit. Although certain characteristics are desirable in terms of inhaler design, our in vitro comparisons of particles generated by the two inhalers should not be extrapolated directly to the clinical situation, where therapeutic doses are selected based on demonstrated pharmacodynamic responses. The higher FPF and the lower extrathoracic deposition of drug delivered by the Breezhaler compared with the HandiHaler are examples of such desirable properties. The higher FPF with Breezhaler (27%) relative to HandiHaler (10%) suggests that a higher proportion of the dose would be delivered to the smaller airways. A higher extrathoracic deposition (71% of the dose delivered by HandiHaler compared with 57% for Breezhaler) would reflect the amount of drug deposited in the mouth and oropharynx and swallowed, giving rise to systemic exposure and a risk of side effects. However, while particle size is determined by the inhaler, the distribution of particles in the lung depends on both particle size and inspiratory flow, 22 and the bronchodilator effect of the drug particles is a complex function of local drug concentration, receptor and airway smooth muscle distribution and the pathology of the disease. While airway smooth muscle is relatively sparse in the alveolar region, this is where β 2 -adrenoceptor density is highest. 23 A β 2 -agonist bronchodilator for COPD, this being a disease primarily of the small airways and alveoli, would ideally be delivered as small particles (FPF) and activate receptors in those regions. Muscarinic receptors on airway smooth muscle are located more densely in the lower trachea and bronchi than in the smaller airways. 24 It was recently shown that patients with a wide range of COPD severity, including very severe, are able to generate adequate inspiratory flows with Breezhaler and that a consistent dose is delivered irrespective of disease severity and age. 21 COPD patients with more severe airways obstruction have been shown to inhale slower through DPIs (compared with patients with less severe impairment) and may have problems achieving an adequate inspiratory flow through high-resistance DPIs. 13, 25, 26 A trend towards increasing patient acceptability with decreasing inhaler resistance has been shown, although the effect plateaued as resistance continued to decrease. 19 Inhaler resistance, although important, is not the only factor contributing to the acceptability of inhalers to patients. Patients found Breezhaler not only more comfortable to 
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inhale through but also simpler to use, and they were more confident that the medication had been taken correctly. Significant differences in scores also favored Breezhaler over the HandiHaler for removing the cap and for opening and closing the mouthpiece. These initial impressions, after a relatively short familiarization period, may be very important to ensure adherence and continued use, which are poor with COPD patients. 9, 27 It seems intuitive that a patient is more likely to use an inhaler that they like and find easy to use, although studies in asthma patients have failed to show an association between inhaler preference and adherence. 28, 29 However, physical difficulty in handling medication has been identified as a significant predictor of low adherence. 
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Comparing single-dose dry-powder inhalers in COPD With the two inhalers evaluated in this study, the proportion of patients completing each step correctly generally increased over the 7 days, reflecting the effects of training and familiarization. For the critical step of releasing the button(s) prior to inhalation, scores were reasonably high on both days with Breezhaler (93% on Day 1 and 96% on Day 2), but were relatively poor (88%) on Day 1 with HandiHaler, increasing 11 percentage points by Day 7. With many inhalers, written instructions alone may be inadequate for successful use and training and familiarization through daily use are required before correct use can be achieved. This was also demonstrated by differences of 9%-11% in the proportion correctly completing other steps with HandiHaler (holding inhaler horizontally, breath holding, and the capsuleremoval procedure). Because Day 1 scores were generally higher with Breezhaler, the differences between Day 1 and Day 7 scores were generally smaller. For the other critical step, about 15% of patients using the Breezhaler and 20% using the HandiHaler failed to breathe out away from the inhaler before inhalation on both Days 1 and 7. These data highlight areas for focusing educational efforts. Continued education and monitoring of inhaler use improve adherence and are critical factors to successful management, and may well have equal or greater importance than inhaler type. 1 It is known that initial appropriate use is lost over time, 19 and continued evaluation of correct inhaler use by treating physicians is especially important among older patients and those receiving multiple medications. 9, 30, 31 In conclusion, most patients used both inhalers correctly after 7 days. Patients preferred the Breezhaler overall and scored it more highly than the HandiHaler for the majority of questions in the preference questionnaire. Breezhaler is a low-resistance inhaler suitable for use by patients with a range of disease severities. These are important factors for ensuring optimum dose delivery, patient adherence with treatment and successful COPD management.
